Last reviewed · How we verify
Acemin (ACEXAMIC ACID)
Acemin (generic name: ACEXAMIC ACID) is a drug. It is currently in Phase 3 development for Skin ulcer.
Acemin works by interacting with specific biological pathways to promote healing in skin ulcers.
Acemin, also known as Aceexamide, is a small molecule drug with unknown drug class and target. It is used to treat skin ulcers and its commercial status is currently unknown. As a small molecule, it is likely to work by interacting with specific biological pathways, but the exact mechanism is not well understood. Further research is needed to determine its safety and efficacy profile. Its development and ownership history are also unclear.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | ACEXAMIC ACID |
|---|---|
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | Phase 3 |
Mechanism of action
Imagine your skin ulcers as a wound that needs to heal. Acemin helps to promote the healing process by interacting with the body's natural repair mechanisms, such as increasing blood flow and reducing inflammation. This allows the wound to heal faster and more effectively.
Approved indications
- Skin ulcer
Common side effects
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Acemin CI brief — competitive landscape report
- Acemin updates RSS · CI watch RSS
Frequently asked questions about Acemin
What is Acemin?
How does Acemin work?
What is Acemin used for?
What is the generic name of Acemin?
What development phase is Acemin in?
Related
- Therapeutic area: All drugs in Dermatology
- Indication: Drugs for Skin ulcer
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing